CytomX

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CytomX and other ETFs, options, and stocks.

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. 

CEO
Sean A. McCarthy
CEOSean A. McCarthy
Employees
69
Employees69
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2010
Founded2010
Employees
69
Employees69

CTMX Key Statistics

Market cap
648.75M
Market cap648.75M
Price-Earnings ratio
-8.19
Price-Earnings ratio-8.19
Dividend yield
Dividend yield
Average volume
3.98M
Average volume3.98M
High today
$3.03
High today$3.03
Low today
$2.82
Low today$2.82
Open price
$2.99
Open price$2.99
Volume
4.60M
Volume4.60M
52 Week high
$8.21
52 Week high$8.21
52 Week low
$1.72
52 Week low$1.72

Stock Snapshot

As of today, CytomX(CTMX) shares are valued at $3.00. The company's market cap stands at 648.75M, with a P/E ratio of -8.19.

As of 2026-06-09, CytomX(CTMX) stock has fluctuated between $2.82 and $3.03. The current price stands at $3.00, placing the stock +6.5% above today's low and -1.1% off the high.

The CytomX(CTMX)'s current trading volume is 4.6M, compared to an average daily volume of 3.98M.

During the past year, CytomX(CTMX) stock moved between $1.72 at its lowest and $8.21 at its peak.

During the past year, CytomX(CTMX) stock moved between $1.72 at its lowest and $8.21 at its peak.

CTMX News

Simply Wall St 5d
Regeneron Pharmaceuticals Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st

...

Regeneron Pharmaceuticals Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st
TipRanks 6d
CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Seeking Alpha 7d
CytomX gains as licensing deal with Regeneron expands

CytomX Therapeutics (CTMX) traded higher in the morning hours on Wednesday after the cancer drug developer announced an expanded collaboration and licensing agr...

CytomX gains as licensing deal with Regeneron expands

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CTMX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.